Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease

American Journal of Health-System Pharmacy

Volumn 63, Issue 8, 2006, Pages 731-734

  Hollands, James M ^a   Foote, Edward F ^b   Rodriguez, Alfonso ^c   Rothschild, John ^c   Young, Steven ^c  

^a BARNES JEWISH HOSPITAL   (United States)

^b WILKES UNIVERSITY   (United States)

^c Renal Consultants of Wyoming Valley   (United States)

Author keywords

Anemia; Drug administration rate; Iron preparations; Iron sucrose; Kidney diseases; Toxicity

Indexed keywords

FERRIC HYDROXIDE SUCROSE;

ANEMIA; ANXIETY DISORDER; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOTENSION; INFUSION RATE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING;

EID: 33646021326     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050173     Document Type: Article

References (16)

1. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999; 69:S61-6.
2. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38:988-91.
3. Silverberg DS, Iaina A, Peer G et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996; 27:234-8.
4. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001; 16:967-74.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 6:31-41.
6. National Cancer Institute. Common toxicity criteria, version 2.0. http://ctep. cancer.gov/forms/CTCv20_4-30-992.pdf (accessed 2006 Jan 19).
7. Venofer (iron sucrose injection) package insert. Shirley, NY: American Regent, Inc.; 2005.
8. Charytan C, Qunibi W, Bailie GR, for the Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100: c55-62.
9. Schwenk MH, Blaustein DA. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney disease. Clin Nephrol 2004; 62:116-20.
10. Blaustein DA, Schwenk MH, Chattopadhyay J et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl. 2003; 87:572-7.
11. Charytan C, Schwenk MH, Al-Saloum MM et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004; 96:c63-6.
12. Kosch M, Bahner U, Bettger H et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001; 16:1239-44.
13. Al-Momen AK, Huraib SO, Mitwallo AH et al. Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO. Saudi J Kidney Dis Transplant. 1994; 5:168-72.
14. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K et al. Indices of iron status in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1999; 34:29-35.
15. Kletzmayr J, Sunder-Plassmann G, Horl WH. High dose intravenous iron: a note of caution. Nephrol Dial Transplant. 2002; 17:962-5.
16. Deicher R, Ziai F, Cohen G et al. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int. 2003; 64:728-36.